Study of the Safety and Efficacy of the Hydroxychloroquine Protocol against COVID-19 in Algeria: Experience of the Gynaecology Department of the EHU Oran

Sharif FZ1,2, Mansur S1,2, Bekhtaoui Ch1,2, Fetati H1,2, Chou H1,2, Bouchrit1,4, and Toumi H1,2,3,*

1EHU Pharmacovigilance Service Oran, Algeria
2Pharmaceutical development research laboratory
3Oran University 1
4Department of Obstetrics and Gynaecology

ABSTRACT
In Algeria, the Scientific Council of the Ministry of Health has decided on the hydroxychloroquine protocol for the treatment of patients with COVID-19, as the hydroxychloroquine molecule has not been the subject of a randomized clinical trial and the therapeutic evidence remains uncertain. The safety of hydroxychloroquine remains dependent on a study to secure and evaluate the efficacy of this protocol in the management of COVID-19 infection. This is a prospective study of 55 patients with COVID-19 hospitalized in the gynaecology department at EHU Oran for a period of one month and confirmed by RT-PCR or thoracoabdominal CT scan. The safety indicator and therapeutic evaluation were based on active reporting of protocol adverse events. In conclusion, the COVID-19 therapeutic protocol is not devoid of adverse effects, even though it brings a benefit, whereas during our study some patients who did not benefit from the protocol showed the same remission rate.

*Corresponding author
M Houari Toumi, Pharmacovigilance Service - Etablissement Hospitalier Universitaire-EHU d’Oran, Algeria. Tel: +213041421579 ; Email: toumi54@live.fr

Received: November 24, 2020; Accepted: December 12, 2020; Published: December 10, 2020

Keywords: COVID-19, Hydroxychloroquine, Azithromycin, Safety, Efficacy

Introduction
The emergence of the COVID-19 epidemic due to SARS-CoV-2, discovered in Wuhan, China in late December 2019, has shaken the world with its rapid spread outside of China to invade many countries around the world [1-3]. The WHO declared the outbreak of COVID-19 as a pandemic on March 12, 2020 (4-5). Algeria is now facing the wave of COVID-19 with a high contamination rate. Among candidate drugs to treat COVID-19, repositioning hydroxychloroquine is an interesting strategy because knowledge of the safety profile, adverse effects, dosage and drug interactions is well known [6,7]. Hydroxychloroquine has demonstrated anti-CoV2 SARS activity in vitro. The clinical safety profile of hydroxychloroquine is better than that of chloroquine and allows for a higher daily dose and has fewer concerns regarding drug interactions, as the hydroxychloroquine molecule has not been subjected to a randomized clinical trial and the anti-CoV2-SRAS therapeutic evidence remains uncertain. The treatment with hydroxychloroquine is recommended with azithromycin by the Algerian Ministry of Health since March 23, 2020, for the moment the results are encouraging however the treatment requires strict monitoring of safety and an estimate of the effectiveness of the molecule [8-10]. The objective of this work is to evaluate the efficacy and safety of the protocol in the treatment of COVID-19 in patients hospitalized in the gynaecology department at EHU Oran.

Material and Method
Type of study
This is a prospective descriptive observational study carried out at the EHU Oran department of gynaecology for one month.

Study Population
COVID-19 in patients undergoing curative treatment were included in this study regardless of their clinical condition. Excluded patients are patients transferred during the treatment period, children hospitalized with their mothers under 12 years of age for preventive treatment.

Method
Data collection, medication and medication review are recorded on a chart and completed by the clinical pharmacy team (Appendix 1); adverse events, complications of hydroxychloroquine and signs of remission will be reported daily throughout the study period. Clinical and biological follow-up for each patient

Protocol for the treatment of COVID-19 in Algeria
For all patients presenting: a moderate form, a form with pneumonia and/or a severe form suspected of a COVID-19 infection: it will be prescribed, in the absence of contraindications and under medical supervision (10).
- Hydroxychloroquine: 200mg, 3 times daily for 10 days.
- Azithromycin: 500mg on the first day then 250mg per day for 4 days.
- Zinc and vitamin C supplementation
Results and Discussion

In this study we recruited 55 patients out of 75 respondents to the inclusion criteria with an average age of 44 years ranging from 12 to 82 years among them six pregnant women. Associated pathologies, hypertension is the most common pathology with a percentage of 32%, of which 45% are under an ACE inhibitor (converting enzyme inhibitor) / ARBII (angiotensin II receptor blocker), then diabetes with a percentage of 27%, of which 20% are insulin-dependent and the others under ADO (oral antidiabetic drugs); hypothyroidism 11%, asthma 7%, other complications estimated at 23% such as ACFA, liver metastasis, breast neoplasia, hypercholesterolemia, chronic gastritis, osteoarthritis and seasonal allergies (See Figure 1).

Figure 1: Percentage of associated co-morbidities

In our population, 93% of symptomatic patients and 7% asymptomatic patients represent the distribution of clinical signs of hospitalized patients respectively; Asthenia 44%, cough 36%, anosmia 36%, dyspnea 33%, agueusia 31%, aches and pains 25%, fever 24%, other signs mainly respiratory, chest pain (DT), runny nose, sneezing with 16% and the other signs with a lower frequency pharyngitis 13%, headache 11%, exacerbation 9%, chills, vomiting, and the others with (7%) (Visual disturbances, sore throat, abdominal pain, muscle pain, loss of appetite) (See Table 1).

Table 1: Clinical signs of COVID 19 and their frequencies

<table>
<thead>
<tr>
<th>Clinical signs</th>
<th>Case</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asthenia</td>
<td>24</td>
<td>44</td>
</tr>
<tr>
<td>All</td>
<td>20</td>
<td>36</td>
</tr>
<tr>
<td>Anosmia</td>
<td>20</td>
<td>36</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>18</td>
<td>33</td>
</tr>
<tr>
<td>Agueusia</td>
<td>17</td>
<td>31</td>
</tr>
<tr>
<td>Curvature</td>
<td>14</td>
<td>25</td>
</tr>
<tr>
<td>Fever</td>
<td>13</td>
<td>24</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>10</td>
<td>18</td>
</tr>
<tr>
<td>DT</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td>sneeze</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td>Nasal discharge</td>
<td>9</td>
<td>16</td>
</tr>
<tr>
<td>Pharyngitis</td>
<td>7</td>
<td>13</td>
</tr>
<tr>
<td>Headache</td>
<td>6</td>
<td>11</td>
</tr>
<tr>
<td>Exacerbation</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>vomiting</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Frisson</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Asymptomatic</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>others</td>
<td>4</td>
<td>7</td>
</tr>
</tbody>
</table>

The duration of hospitalization of patients is five days according to the ministerial instruction, except for severe and critical cases (pregnant women, respiratory distress, cardiac disorders) 90% of the forms observed are considered benign and are mainly anosmia, agueusia, chest pain, cough, headache, and asthenia, for the remaining 10% developed a moderate to severe form, of which 3% required respiratory assistance.

Thus, according to our study, 84% of hospitalized patients are under hydroxychloroquine protocol, 30% of which saw a decrease in fever and chills after the first two days, 42% of the main signs that disappear on the 3rd day are agueusia, anosmia, chills, fever, dyspnea and aches and pains, for some symptoms persist until the 4th or even the 5th day of treatment, mainly respiratory signs including cough and dyspnea 21%.

The remaining 16% of patients who did not benefit from the national protocol had a contraindication to hydroxychloroquine (ACFA, extended TQ); these benefited from treatment with lovenox as a preventive measure, azithromycin, vitamin C, zinc; the reduction in signs was similar to those under treatment with hydroxychloroquine (Figure 2). Our study is similar to the study by Gautret et al. on the clinical efficacy of the hydroxychloroquine and azithromycin protocol, however in our study there was no significant difference between patients treated with the hydroxychloroquine and azithromycin protocol and patients without hydroxychloroquine.

Figure 2: Percentage remission of clinical signs of COVID-19 as a function of time

Regarding safety indicators, the adverse events reported daily are mainly digestive; diarrhea and vomiting 14.40% in the first 3 days, heart problems, palpitations 4.11% and only one case of QT wave lengthening, the latter was the subject of a pharmacovigilance investigation whose accountability studies proposed close clinical monitoring and close ECGs, other cases noted (visual disturbances, muscle weakness, bruising of the lower limb). Although the pregnancy safety data for hydroxychloroquine are insufficient, our patients did not develop any serious adverse effects and were tolerant to treatment with tolerable diarrhea.

Figure 3: Percentage of reported cases of adverse events
In conclusion, through this work, we wanted to make our modest contribution in the field of management of patients contaminated by SARS-CoV 2. In this work we evaluated the impact of remission through the symptomatology that are the first signs that disappear after treatment with the hydroxychloroquine protocol. We were surprised to find that a segment of the population without treatment had recovered from their COVID-19.

Finally, our study is a first step towards strengthening the immunity of patients.

Study Bias
Short study time; hence insufficient sample size to obtain conclusive results

References
10. Note N012 of March 23, 2020 relating to the implementation of the COVID-19 patient management system.